Skip to main content
Top
Published in: Diabetologia 1/2015

01-01-2015 | Letter

Linking prediabetes and cancer: a complex issue

Authors: Dario Giugliano, Maria Ida Maiorino, Katherine Esposito

Published in: Diabetologia | Issue 1/2015

Login to get access

Excerpt

To the Editor: We read with interest the meta-analysis by Huang et al [1] on the association between prediabetes and risk of cancer. In this article, prediabetes was defined as being a general term referring to an intermediate stage between normoglycaemia and overt diabetes [1]. Based on the data obtained from 13 cohorts (as indicated in Fig. 2 of their paper), the authors concluded that prediabetes was associated with a 15% increased risk for the general population of developing cancer. Overall, the findings seem to be in line with the evidence of a positive association between diabetes and cancer [2]; as for other diabetic complications, including cardiovascular complications, the association seems to encompass both the diabetic and prediabetic states. Type 2 diabetes is associated with an increased risk of several cancer types, including postmenopausal breast, colorectal, endometrial, liver and pancreatic cancer, and non-Hodgkin’s lymphoma [2]. These associations seem to be independent of BMI. Furthermore, patients with pre-existing diabetes who develop cancer have increased short-term and long-term mortality compared with non-diabetic patients [3]. …
Literature
1.
go back to reference Huang Y, Cai X, Qiu M et al (2014) Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57:2261–2269PubMedCrossRef Huang Y, Cai X, Qiu M et al (2014) Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57:2261–2269PubMedCrossRef
2.
go back to reference Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375:2201–2202PubMedCrossRef Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375:2201–2202PubMedCrossRef
3.
go back to reference Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764PubMedCentralPubMedCrossRef Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764PubMedCentralPubMedCrossRef
4.
go back to reference Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35:2402–2411PubMedCentralPubMedCrossRef Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35:2402–2411PubMedCentralPubMedCrossRef
5.
go back to reference Alberti KGMM, Eckel RH, Grundy SM et al (2009) International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef Alberti KGMM, Eckel RH, Grundy SM et al (2009) International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef
6.
go back to reference Esposito K, Chiodini P, Capuano A et al (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44:634–647PubMedCrossRef Esposito K, Chiodini P, Capuano A et al (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44:634–647PubMedCrossRef
7.
go back to reference Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef
8.
go back to reference Esposito k, Ciardiello F, Giugliano D (2014) Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46:39–42PubMedCrossRef Esposito k, Ciardiello F, Giugliano D (2014) Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46:39–42PubMedCrossRef
Metadata
Title
Linking prediabetes and cancer: a complex issue
Authors
Dario Giugliano
Maria Ida Maiorino
Katherine Esposito
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3426-2

Other articles of this Issue 1/2015

Diabetologia 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine